HC Wainwright reiterated their buy rating on shares of Talphera (NASDAQ:TLPH – Free Report) in a research note issued to investors on Friday morning, Benzinga reports. The brokerage currently has a $6.00 target price on the stock. HC Wainwright also issued estimates for Talphera’s Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.29) EPS and Q4 2025 earnings at ($0.32) EPS.
Separately, Maxim Group assumed coverage on Talphera in a research report on Monday, May 6th. They set a buy rating and a $3.00 price target on the stock.
Check Out Our Latest Analysis on TLPH
Talphera Trading Up 2.6 %
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Talphera stock. Turtle Creek Wealth Advisors LLC purchased a new position in Talphera, Inc. (NASDAQ:TLPH – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 71,500 shares of the company’s stock, valued at approximately $64,000. Turtle Creek Wealth Advisors LLC owned 0.42% of Talphera at the end of the most recent reporting period. Institutional investors and hedge funds own 37.67% of the company’s stock.
About Talphera
Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.
Featured Articles
- Five stocks we like better than Talphera
- What is the Shanghai Stock Exchange Composite Index?
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Ride Out The Recession With These Dividend Kings
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Roth IRA Calculator: Calculate Your Potential Returns
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.